Execs On The Move, July-August 2014
Executive Summary
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Advertisement
Topics
- Industries
- BioPharmaceutical
- Medical Device
Related Companies
- Epic Sciences Inc.
- Ocera Therapeutics Inc.
- Gelesis Inc.
- Ascendis Pharma AS
- Avalanche Biotechnologies Inc.
- Pfizer Inc.
- Agios Pharmaceuticals Inc.
- Ignyta Inc.
- Kite Pharma Inc.
- NeoChord Inc.
- Eiger BioPharmaceuticals Inc.
- NeuroSigma Inc.
- MYOS RENS Technology Inc.
- KineMed Inc.
- Neos Therapeutics Inc.
- Regado Biosciences Inc.
- Synergy Pharmaceuticals Inc.
- KineMed Inc.
- Nektar Therapeutics
- Global Blood Therapeutics Inc.
- Vaxart Inc.
- Orthofix Medical Inc.
- Singulex Inc.
- Acorda Therapeutics Inc.
- OMNIlife science Inc.
- Cellectar Biosciences Inc.
- Atossa Genetics Inc.
- NanoLogix Inc.
- Spinifex Pharmaceuticals Pty. Ltd.
- GenMark Diagnostics Inc.
- Enzo Biochem Inc.
- Exosome Diagnostics Inc.
- Senseonics Holdings Inc.
- Seres Therapeutics Inc.
- Global Blood Therapeutics Inc.
- Merck Serono SA
- Array BioPharma Inc.
- Global Blood Therapeutics Inc.
- AbbVie Inc.
- Clarus Therapeutics Inc.
- Windtree Therapeutics Inc.
- NeuWave Medical Inc.
- Cara Therapeutics Inc.
- G1 Therapeutics Inc.
- Pharmacyclics Inc.
- Forma Therapeutics Holdings LLC
- BioNano Genomics Inc.
- Windtree Therapeutics Inc.
- Array BioPharma Inc.
- Genkyotex SA
- Scil Proteins GmbH
- Celgene Corp.
- OxiGene Inc.
- Jazz Pharmaceuticals PLC
- Celgene Corp.
- ERBA Diagnostics Inc.
- Ignyta Inc.
- Global Blood Therapeutics Inc.
- IMV Inc.
- Parexel International Corp.
- QRxPharma Ltd.
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IV004255
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
IV004255
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.